Longitudinal Relationship between Idylla Plasma ct BRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma

ConclusionsOverall, interim ctDNA results provided evidence of partial response or progressive disease an average of 82 days before radiography. This pilot study supports the feasibility of using the Idylla plasmaBRAF V600 ctDNA assay as a complement to CT scanning for routine monitoring of therapeutic response. Somatic mutation quantification based on Cq values shows promise for identifying disease progression and warrants further validation.
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research